Skip Navigation
People
Events
News
LinkedIn
Twitter
Instagram
Facebook
YouTube
Email
People
Events
News
Search site:
National Cancer Institute
Research & Technology
KRAS G12C
RAS drug discovery at Frederick National Laboratory reaches lung cancer patients in a clinical trial
A first-in-human study seeks to determine the drug’s safety and tolerability and to detect potential antitumor activity.
Program Overview
Retroviral Evolution Section
Retroviral Pathogenesis Section
Retrovirus-Cell Interaction Section
Viral Oncology Section
Viral Persistence Section
Sections
Biological Products Core
Cellular Immunity Core
HIV Molecular Monitoring Core
Nonhuman Primate Research Support Core
Quantitative Molecular Diagnostics Core
Tissue Analysis and Retroviral Protein Chemistry Core
Viral Evolution Core
Cores
AIDS and Cancer Virus Program
Program Overview
Computational Structural Biology Section
Epigenetics Section
HLA Immunogenetics Section
Molecular Immunology Section
Basic Science Program
Program Overview
Advanced Biomedical Computational Science
Center for Technical Operations Support
Bioinformatics and Computational Science
Program Overview
Advanced Cryo-Electron Microscopy Technology Group
Antibody Characterization Laboratory
Cancer Data Science Initiatives
CLIA Molecular Diagnostics Laboratory
Imaging Mass Cytometry Laboratory
Protein Expression Laboratory
Cancer Research Technology Program
Program Overview
Animal Diagnostics Laboratory
Animal Research Technical Support
Center for Advanced Preclinical Research
Genome Modification Core
Gnotobiotics Facility
Laboratory Animal Medicine
Molecular Histopathology Laboratory
Mouse Modeling and Cryopreservation
Small Animal Imaging Program
Laboratory Animal Sciences Program
Program Overview
Cancer Immunoprevention Laboratory
Center of Excellence for Serology Development and Emergency Preparedness
HPV and COVID-19 Serology Laboratories
SeroNet Coordinating Center
Vaccine, Immunity, and Cancer Directorate
Science Areas
Program Overview
AIDS Monitoring Laboratory
Bioprocessing Laboratory
Blood Processing Core
Clinical Support Laboratory
Flow Cytometry Support Laboratory
Immunological Monitoring Laboratory
Laboratory of Human Retrovirology and Immunoinformatics
Laboratory of Molecular Cell Biology
Neutrophil Monitoring Laboratory
Radiochemistry Program
Virus Isolation and Serology Laboratory
Clinical Services Program
Cancer Imaging Informatics Laboratory
Clinical Pharmacodynamics - Biomarkers Program
In Vitro
Evaluation and Molecular Pharmacology Laboratories
In Vivo
Evaluation Program
Investigative Toxicology Laboratory
NExT Chemical Biology Consortium Support Programs
Natural Products Support Group
Pharmacokinetics and Drug Analysis Group
Radiochemistry Support Group
DCTD Support
Applied and Developmental Research Directorate
Biopharmaceutical Development Program
Clinical Monitoring Research Program
Program Overview
Biospecimen Research Group
Cancer Genomics Research Laboratory
Drug Discovery and Development Program
Molecular Characterization Laboratory
Clinical Research Directorate
Vaccine Clinical Materials Program
Clinical Trial Support
CTDC
New cancer data commons expands available clinical and translational data
FNL GCREM
New training series for rapid response clinical research available for free
Virtual training series aims to educate and empower clinical researchers to perform rapid response clinical studies in atypical environments.
Innovation & Initiatives
RAS Initiative Symposium 2024
Progress against RAS-driven cancers lauded at RAS Symposium, with more candidate treatments on the horizon
RAS Initiative
Scientific Standards Hub
SeroNet
Support for Global Initiatives
Initiatives
Center for Innovation and Strategic Partnerships
Patents
Innovation
Biotech Connector
High Fidelity
Life Sciences Symposium
RAS Initiative Symposium
Scientific Partners Distinguished Lecture Series
Technology Showcase
Women in Science Speak
Scientific Series
Newsletter
Summer 2024 SeroNews
Latest edition of SeroNews highlights viral evolution.
Importance of innovation
Within FNL, innovation plays a pivotal role in delivering new and enhanced technologies that empower us to tackle essential scientific inquiries, enhance our services, and ultimately contribute to the wellbeing of patients.
Vladimir Popov, Ph.D., MBA
High Fidelity
Dec 9, 2024
How Much Should I Trust NGS Data: A View from Regulatory Science
Investigator Resources
Apply Now-Feb. 14
Cancer Reagent Target Requests
Interested researchers with readily available protein/peptides can submit a request for antibody generation.
BRB Preclinical Biologics Repository
SeroNet Study Collections
dbGuide
NCI Mouse Repository
sgRNA Scorer
More Repositories
Data & Repositories
Nanotechnology Characterization Laboratory
National Cryo-Electron Microscopy Facility
National Scientific User Facilities
cGMP Training
FNL Global Clinical Research Educational Modules
Project Management Night Out Seminar Series
Training & Education
Program Overview
Cellular or Tissue SIV/SHIV RNA and DNA testing
HIV/SIV Single Genome Amplification and Sequencing
Lineage-specific Next Gen Multiplex
In Situ
Hybridization for HIV or SIV RNA and DNA
Next-generation sequencing analysis of barcoded SIV, SHIV, or HIV
Novel CD4+ T Cell Specific Immunohistochemistry Detection and Analysis
Plasma or CSF SIV/SHIV RNA measurements
Quantitative Assessment of Lymphoid Tissue Fibrosis
Quantitative assessment of HIV or SIV viral DNA in laser capture microdissected immune cells
Viral Integration Site Analysis (VISA) for HIV studies
HIV/SIV Services
Assessment of Drug Efficacy in a Survival Study
In Vitro
Cell Cytotoxicity Evaluation
Pharmacokinetic Evaluation in Kras/p53 PDAC Mice
Time Course Assessment of Tumor Response to Therapeutics
Tolerance Evaluation of Experimental Compound in Kras/p53 PDAC Mice
Use of Mouse Embryonic Stem Cells Expressing miRNAs
Laboratory Animal Services
An
in vitro
drug release study in human plasma
Pharmacokinetic study of nanomedicine in rats
Nanomedicine & Nanoformulation
Detection of Mycobacterium tuberculosis DNA
Other
Technical Services
AI and Data Science
Antibody Science
Biospecimen Assays
Biopharmaceutical Development
Electron Microscopy
HPV Serology Operating Procedures
Human SARS-CoV-2 Serology Standard
Nanotechnology
Protein Science
Universal Standards & Reference Materials
SIV/SHIV
Barcode Analysis Tool
Download files to demultiplex next-generation sequencing and determine the abundance of individually barcoded SIV/SHIV viral lineages.
Assay Cascade Characterization Program
Next deadline to apply: March 3, 2025
Preclinical characterization of nanoparticles to facilitate the regulatory review of nanotechnology concepts intended as cancer therapies and diagnostics.
Researcher Resource
New training for rapid response clinical research
Learn about challenges in clinical research during emergency infectious disease outbreaks and strategies to overcome them.
Did you know?
We are home to unique scientific expertise and technological capabilities available nowhere else. The Technical Services Program through the Partnership Development Office makes some of these capabilities and services readily available to the external research community at-cost to advance biomedical research around the world.
FNL Initiative
Scientific Standards Hub
Collection of scientific groups at FNL working to develop, deposit and share standards and references in biological research.
Work With Us
Register Your Interest
Become a Vendor
Potential vendors seeking to work with us must first complete a New Vendor Registration.
Partnership Development Office
Partnership Mechanisms
Academic Partnerships
Collaboration
Intellectual Property and Strategic Agreements
Tech Transfer & Licensing
Become a Vendor
Business Opportunities
Contracts and Acquisitions
Small Businesses, Nonprofits & HBCUs
Vendors & Subcontractors
2024 Tech Showcase
Technology Showcase team blends new and old approaches for 2024 event
Innovation
FNL Patents
Virtual training series aims to educate and empower clinical researchers to perform rapid response clinical studies in atypical environments.
solicitation
Closed 1 week 3 days ago (11/22/2024)
Commercial Goods/Services
B25132
Careers
What do you enjoy about working at the Frederick National Laboratory?
I enjoy coming to work every day because of the wonderful team we have.
Chris Karlovich, Ph.D.
Job Opportunities
Application Process
Benefits
Diversity and Inclusion
Internships and Fellowships
About FNL
Did you know?
In the 10-year period 2012-2022, the Vaccine Clinical Materials Program completed 300+ shipments supporting approximately 100 clinical trials across 45 products.
Who We Are
Mission & Core Values
Community Outreach
People
Publications
History
Menu
Research
Initiatives
Resources
Collaborations
Careers
About
Search site:
Twitter
LinkedIn
Facebook
Instagram
YouTube
Email
National Cancer Institute
Mouse Repository: ES Cell Resource
Frederick National Laboratory
Science & Technology
Technology
NCI Mouse Repository Home
LASP Mice Models - Home